Immunex Selected by FORTUNE(R) Magazine as One
Of the "100 Best Companies to Work For"
SEATTLE, Dec. 18 /PRNewswire/ -- FORTUNE Magazine announced today that
Immunex Corporation (Nasdaq: IMNX) has been selected as one of the
"100 Best Companies to Work For." This prominent list of companies will be
featured in the December 25, 2000 issue of FORTUNE.
"Immunex employees are creating the future of medicine by working together
in an exceptionally spirited environment," said Ed Fritzky, Immunex chairman,
chief executive officer and president. "We find that employees respect and
trust their colleagues and constantly strive as a team to elevate performance
standards."
"Immunex routinely surveys employee attitudes to determine how to improve
the work environment," said Kathy Spencer, Immunex vice president of human
resources. "Our goal has been to achieve employer of choice status in our
very competitive industry. We are gratified with being selected as one of the
100 Best Companies to Work For."
Immunex was selected based on responses from 250 randomly chosen Immunex
employees who were surveyed by FORTUNE Magazine. Two-thirds of the evaluation
is based on feedback from employees. Also taken into consideration was
information regarding workplace practices, employee benefits, and company
information from annual reports, company newsletters and news stories.
About Immunex
Immunex is dedicated to creating the future of medicine. Today, the
company markets innovative therapeutic products including NOVANTRONE(R)
(mitoxantrone for injection concentrate), ENBREL(R) (etanercept) and
LEUKINE(R) (sargramostim). In addition to the treatment of multiple
sclerosis, rheumatoid arthritis and cancer, Immunex has multiple products
being developed for several different markets as part of its existing products
and new product development programs.
Also, for its reputation as a technology leader in its field, Immunex has
received national recognition this year such as the selection by Red Herring
Magazine as one of the top 50 companies "most likely to change the world."
Resulting from its business success in 2000 and completion of the largest
stock offering in healthcare history, Immunex moves forward strategically well
positioned as it enters a new era of industry growth and prosperity.
Immunex Corporation is a leading biopharmaceutical company dedicated to
improving lives through immune system science innovations.
NOTE: This news release contains forward-looking statements that involve
risks and uncertainties, including risks associated with clinical development,
regulatory approvals, our reliance on third-party manufacturers, product
commercialization and other risks described from time to time in the SEC
reports filed by Immunex, including the most recently filed Form 10-Q. An
electronic version of this news release -- as well as additional information
about Immunex of interest to investors, customers, future employees and
patients -- is available on the Immunex home page at http://www.immunex.com.
SOURCE Immunex Corporation
 back to top
Related links:
http://www.immunex.com
Company News On-Call:
http://www.prnewswire.com/comp/434644.html or fax,
800-758-5804, ext. 434644
CONTACT:
press, Kris Greco, 206-470-4871, or
investors, Mark Leahy, 206-389-4363, both of Immunex Corporation
|
